ABSTRACT
Progress in material science and nanotechnology has propelled the evolution of biom aterials with improved quality and extended patent life [1]. However, even in the 2 1 st century, the struggle to create surfaces that interact actively with the biological environment and evoke the same sequence of effects as the corporal tissues do, still continues. Tailoring the interface compatibility of biomaterials through surface modification thus becom es indispensable in the optimization of physiological interactions and clinical performance. Since the original discovery by Folkman and Long in 1964, polymeric materials, with their endless diversity in topology and architecture,
have occupied a m ajor status in the fabrication of controlled drug delivery systems [2]. A variety of polymers, ranging from synthetic, natural, to hybrid, have been scrutinized for the synthesis of biodegradable nanoparticles. The optimal formulation for every particular drug delivery application is delineated by the specificities of the polymer used and the process of nanoparticle preparation. The minimal toxicity and biodegradability of aliphatic polyesters like poly(lactic-co-glycolide) (PLGA) has propelled its wide spread usage in controlled release technology [3].
